How to Buy Sab Biotherapeutics Stock
Sab Biotherapeutics Inc
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies built upon human antibodies.
Sab Biotherapeutics stock last closed at $4.00, up 3.63% from the previous day, and has increased 124.72% in one year. It has overperformed other stocks in the Biotechnology industry by 1.96 percentage points. Sab Biotherapeutics stock is currently +139.52% from its 52-week low of $1.67, and -39.39% from its 52-week high of $6.60.
At the moment, there are 76.46M SABS shares outstanding. The market value of SABS is $305.86M. In the past 24 hours, 2.36M SABS shares were traded.
How to Buy Sab Biotherapeutics Stock
Wondering how to invest in Sab Biotherapeutics stock? Here's how.
- Decide where to buy Sab Biotherapeutics stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you figure out where to buy Sab Biotherapeutics stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Fund your brokerage account: Select your payment method and add your information.
- Research Sab Biotherapeutics stock: The Sab Biotherapeutics ticker symbol is SABS. Is Sab Biotherapeutics stock a good investment? Should you buy shares of SABS? How do SABS's underlying business fundamentals look? Do top analysts think Sab Biotherapeutics is a good buy? Why has SABS's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if SABS is a good stock to buy).
- Make your SABS purchase: Decide if you will purchase SABS shares at the current market price or use a limit order to purchase SABS stock at a specific price.
- Get updates on your SABS investment: Create a watchlist to watch your new investment in Sab Biotherapeutics shares.
Step 1: Decide where to buy Sab Biotherapeutics stock
You need an online brokerage account to access the NASDAQ market and buy SABS shares.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Tech to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal details so you can invest in SABS today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to create a new trading account.
- Send your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've filled out your info on one of the best stock market apps, you can securely and quickly fund your account:
Check out the video below if you need help depositing money into your investment account.
Step 4: Research Sab Biotherapeutics stock
Once you have identified the best place to buy Sab Biotherapeutics stock, it's crucial to research their stock before you buy, so you actually understand the risk and upside.
Sab Biotherapeutics Metrics
SABS Overview
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on SABS's stock page.
Is SABS stock properly valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge SABS's fair value.
Using relative valuations measures:
- SABS may be undervalued based on its P/B ratio of 1.35x, relative to Biotechnology industry P/B ratio of 4.95x
You can do additional valuation research on SABS's stock here.
A look at SABS Cashflows and Balance Sheet
Pros:
- SABS has cash burn of 53163220. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the SABS balance sheet.
- SABS has a low debt to equity ratio of 0.09.
- There are more short-term assets than long-term liabilities on the SABS balance sheet.
Cons:
- SABS has $107.39M in cash and short term investments. This is not enough to cover its annual cash burn of $53.16M.
Is SABS stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 8 Equities analysts who give forecasts on SABS, the consensus analyst rating on SABS is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent SABS Analyst Ratings
Seema Sheoran, a bottom 33% analyst from Rodman & Renshaw reiterates SABS with a strong buy rating and maintains their SABS price target from $13.00 to $13.00, on May 11, 2026.
Michael Yee, a top 17% analyst from UBS initiates coverage on SABS with a strong buy rating and announces their SABS price target of $7.00, on Jan 7, 2026.
Yatin Suneja, a top 3% analyst from Guggenheim initiates coverage on SABS with a strong buy rating and announces their SABS price target of $15.00, on Dec 19, 2025.
You can dig deeper into what analysts are forecasting on the Sab Biotherapeutics stock forecast page.
SABS Momentum
Is SABS Making Money?
Last year, SABS revenue was $0.00. In the past four year, SABS's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 32.37%.
You can research SABS's earnings and revenue performance here.
What are SABS insiders up to?
In the past year, executives and large shareholders at SABS have bought more shares than they have sold.
Andrew Moin, Director of SABS, was the latest SABS insider to buy. They bought $3,045,000.00 worth of SABS shares on Sep 29, 2025.
Research more about who owns SABS shares here.
Does SABS stock generate passive income?
No, Sab Biotherapeutics doesn't provide an income stream by paying out dividends.
What others are saying about SABS
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your SABS purchase
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly fine. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific price, place a limit order.
Hit the Open Trade button and your broker will execute the order.
If you require additional help with buying stocks on eToro, click the helpful video below:
Step 6: Get updates on your SABS investment
Now that you own some SABS shares, you'll want to stay up-to-date on your investment.
Start a watchlist to get alerted to the latest events about your SABS stock.
SABS Feed
How to Buy Stock in Sab Biotherapeutics
To reiterate, here are the 6 steps for buying Sab Biotherapeutics stock:
- Decide where to buy Sab Biotherapeutics stock
- Create a brokerage account
- Fund your brokerage account
- Research Sab Biotherapeutics stock
- Make your SABS purchase
- Get updates on your SABS investment
If you need a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep an eye on your investment in Sab Biotherapeutics, hit the button below to create your watchlist.
Other Content You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.